Rexahn Pharmaceuticals, Inc.  

(Public, NYSEMKT:RNN)   Watch this stock  
Find more results for NYSEAMEX:RNN
+0.014 (2.55%)
Sep 4 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.52 - 0.56
52 week 0.50 - 0.95
Open 0.53
Vol / Avg. 175,777.00/306,683.00
Mkt cap 99.38M
P/E     -
Div/yield     -
EPS -0.06
Shares 180.70M
Beta 0.33
Inst. own 9%
Nov 11, 2015
Q3 2015 Rexahn Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 16, 2015
Rexahn Pharmaceuticals Inc at EBD Group BioPharm America - 1:45PM EDT - Add to calendar
Sep 10, 2015
Rexahn Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference - 11:40AM EDT - Add to calendar
Sep 9, 2015
Rexahn Pharmaceuticals Inc at FBR Healthcare Conference Add to calendar
Aug 10, 2015
Q2 2015 Rexahn Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -44.85% -69.77%
Return on average equity -57.90% -94.48%
Employees 22 -
CDP Score - -


Suite 455, 15245 Shady Grove Road
United States - Map
+1-240-2685300 (Phone)
+1-240-2685310 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company has three clinical stage drug candidates in active development: Archexin, a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including colon, lung and pancreatic cancer, and Supinoxin (RX-5902), a small molecule that inhibits the phosphorylation of p68, which is expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation or tumor growth of cancer cells. The Company also has two drug candidates in pre-clinical development: Archexin-Nano and RX-21101.

Officers and directors

Peter C. Brandt Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Chang H. Ahn Chairman Emeritus, Chief Scientist
Age: 63
Bio & Compensation  - Reuters
Peter D. Suzdak Ph.D. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Tae Heum Jeong Chief Financial Officer, Secretary
Age: 44
Bio & Compensation  - Reuters
Ely Benaim Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Charles G. Beever Independent Director
Age: 62
Bio & Compensation  - Reuters
Mark P. Carthy Independent Director
Age: 54
Bio & Compensation  - Reuters
Kwang Soo Cheong Independent Director
Age: 54
Bio & Compensation  - Reuters
Richard J. Rodgers Independent Director
Age: 48
Bio & Compensation  - Reuters